A 40% complication rate sounds very different when its denominator is specified. A historical toxicology-service study found rhabdomyolysis in 22 of 55 methamphetamine cases, but those cases had already met requirements for symptomatic toxicity and laboratory evaluation. The percentage does not estimate the chance of muscle injury after any methamphetamine exposure.
Who entered the study?
O’Connor and colleagues retrospectively reviewed a tertiary-center medical toxicology service during January 2010–January 2013. Inclusion required documented sympathomimetic toxicity, comprehensive urine GC–MS and a serum creatine kinase (CK) measurement. The study included 102 patients overall; 89 entered single-stimulant comparisons. The methamphetamine group also required amphetamine identification. O’Connor et al., 2015.
Rhabdomyolysis was defined as CK above 1,000 IU/L and severe rhabdomyolysis as above 10,000 IU/L. Among 55 methamphetamine cases, 22 met the first definition and two the second. Synthetic-cathinone cases had 12/19 and 5/19, respectively. Missing testing, retrospective documentation, unrecognized novel substances and possible caffeine contributions limited interpretation. Definitions, results and limitations.
Why does the toxicity requirement matter?
People with a positive test but no documented clinical toxidrome were outside the study’s selected population. So were people without the required testing. The numerator is therefore conditioned on a clinical pathway that is likely to differ from uncomplicated exposure in the community.
Confirmatory testing makes the exposure classification more specific, but it does not undo selection into the hospital or toxicology service. Analytical confidence about which drug was detected and epidemiological confidence about whom a percentage represents are separate strengths.
Why retain the CK thresholds?
A threshold defines which cases count toward an endpoint. Reporting “muscle injury” without retaining the study’s CK rule can make results appear comparable with papers using different definitions. Likewise, combining the severe endpoint with the broader endpoint would count nested categories as though they were independent complications.
The two severe cases are part of the 22 rhabdomyolysis cases. They are not two additional patients to add to 22. A statement that “40% had severe rhabdomyolysis” would substitute the broader numerator for the severe one and materially overstate the result.
What did a single-stimulant classification exclude?
The study’s grouping rule describes the substances identified and classified by its methods. It is not equivalent to laboratory proof that no other pharmacologically relevant exposure occurred. That distinction matters when attributing all clinical findings to one detected stimulant or comparing results across laboratories with different testing panels.
Similarly, the comparison with synthetic cathinones addresses selected toxicity cases involving particular classes. It cannot rank the safety of all street products, establish equal administered doses or estimate which substance an unknown mixture contained.
How should this evidence inform an individual assessment?
The paper supports considering muscle injury as a meaningful complication in this clinical setting. Case-specific attribution still needs the actual CK course, symptoms, temperature, exertion, immobilization, other exposures and renal findings. The urine result establishes exposure evidence; the CK measurement addresses a different biological question. Neither alone identifies the full mechanism.
This is a historical observational series, not a controlled dosing experiment or a current treatment guideline. Its most transferable lesson is to preserve the selected population and endpoint definition beside the percentage.
Source
O’Connor AD, Padilla-Jones A, Gerkin RD, Levine M. Prevalence of Rhabdomyolysis in Sympathomimetic Toxicity: a Comparison of Stimulants. Journal of Medical Toxicology. 2015;11:195–200. doi:10.1007/s13181-014-0451-y.